Adverse events in lymphoma patients treated with phosphoinositide 3 kinase Inhibitor in clinical trials: a meta-analysis

Shan, WH; Wu, GX; Huang, YT; Zeng, HY; Xia, WL; Lin, ZJ; Xu, B

Lin, ZJ; Xu, B (通讯作者)，Xiamen Univ, Affiliated Hosp 1, Sch Med, Dept Hematol, Xiamen 361102, Peoples R China.;Lin, ZJ; Xu, B (通讯作者)，Xiamen Univ, Inst Hematol, Xiamen 361102, Peoples R China.;Lin, ZJ; Xu, B (通讯作者)，Key Lab Xiamen Diag & Treatment Hematol Malignanc, Xiamen 361102, Peoples R China.;Xia, WL (通讯作者)，Sun Yat Sen Univ, JieYang Affiliated Hosp, Jieyang Peoples Hosp, Dept Hematol, Jieyang, Guangdong, Peoples R China.

ANNALS OF HEMATOLOGY, 2022; 101 (8): 1741

Abstract

Background Malignant lymphomas are one of the most common cancers worldwide and with high biologic heterogeneity, while the phosphoinositide 3 kinase ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索